{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+high+dose",
    "query": {
      "intervention": "Empagliflozin high dose"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+high+dose&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T20:41:45.849Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01422876",
      "title": "Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "high dose FDC",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "high dose FDC placebo",
          "type": "DRUG"
        },
        {
          "name": "low dose FDC placebo",
          "type": "DRUG"
        },
        {
          "name": "high dose BI 10773 placebo",
          "type": "DRUG"
        },
        {
          "name": "low dose FDC",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "linagliptin",
          "type": "DRUG"
        },
        {
          "name": "linagliptin placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 low dose placebo",
          "type": "DRUG"
        },
        {
          "name": "low dose BI 10773 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1405,
      "start_date": "2011-08",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-02",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 112,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422876"
    },
    {
      "nct_id": "NCT01177813",
      "title": "Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo identical to BI10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "BI 10773",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 open label",
          "type": "DRUG"
        },
        {
          "name": "Placebo identical to BI10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo identical to Sitagliptin 100mg",
          "type": "DRUG"
        },
        {
          "name": "BI10773",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 986,
      "start_date": "2010-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 27,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01177813"
    },
    {
      "nct_id": "NCT01131676",
      "title": "BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BI 10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo BI 10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo BI 10773 low dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7064,
      "start_date": "2010-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-05-16",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 170,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 140 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01131676"
    },
    {
      "nct_id": "NCT01164501",
      "title": "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Renal Insufficiency"
      ],
      "interventions": [
        {
          "name": "BI 10773",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 741,
      "start_date": "2010-07",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 18,
      "location_summary": "Anaheim, California • Lomita, California • Plantation, Florida + 15 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01164501"
    },
    {
      "nct_id": "NCT01289990",
      "title": "Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BI 10773",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin 100mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2705,
      "start_date": "2011-02",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-07-15",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01289990"
    },
    {
      "nct_id": "NCT03152552",
      "title": "A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus and Heart Failure"
      ],
      "interventions": [
        {
          "name": "LIK066",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2017-07-25",
      "completion_date": "2018-06-06",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 21,
      "location_summary": "Huntsville, Alabama • Carmichael, California • Concord, California + 18 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03152552"
    },
    {
      "nct_id": "NCT01210001",
      "title": "Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 499,
      "start_date": "2010-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-17",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 24,
      "location_summary": "Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01210001"
    },
    {
      "nct_id": "NCT02106923",
      "title": "Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "1 tablet Empagliflozin/2 tablets Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "10 mg Empagliflozin/1000 mg Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "1 tablet 10 mg Empagliflozin/3 tablets Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "2 tablets 5 mg Empagliflozin/750 Metformin XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 72,
      "start_date": "2014-04",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2017-03-09",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02106923"
    },
    {
      "nct_id": "NCT02580591",
      "title": "Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 977,
      "start_date": "2015-12-22",
      "completion_date": "2017-09-20",
      "has_results": true,
      "last_update_posted_date": "2018-11-02",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 39,
      "location_summary": "Montgomery, Alabama • Concord, California • Fresno, California + 33 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02580591"
    },
    {
      "nct_id": "NCT02121483",
      "title": "Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "empagliflozin medium dose",
          "type": "DRUG"
        },
        {
          "name": "empagliflozin high dose",
          "type": "DRUG"
        },
        {
          "name": "empagliflozin low dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 27,
      "start_date": "2014-06",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2016-09-19",
      "last_synced_at": "2026-09-26T20:41:45.849Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Toledo, Ohio + 2 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02121483"
    }
  ]
}